Bassel F. El‐Rayes

This study identifies key oncogenic pathways and targetable genes in MEN1-wild-type low-grade pancreatic NETs that drive metastasis, offering a therapeutic strategy based on pathway intensity rather than mutation count.

Oral PDE10 inhibitor ADT-030 curbed KRAS-mutant pancreatic cancer growth and metastasis in mouse models, stayed active in KRAS-inhibitor-resistant cells, and shifted tumor immune profiles.

ProAgio, an integrin αvβ3-targeted cytotoxin, enhances GPH therapy in PDAC by modulating the tumor microenvironment and improving immune responses.

This study shows that combining PCNA inhibitor AOH1996 with KRAS inhibitors enhances antitumor activity in pancreatic cancer models.

This paper shows that combining Eltanexor and MRTX1133 improves efficacy in KRASG12D mutant PDAC by overcoming resistance and reducing tumor growth.

ADT-1004, a pan-RAS inhibitor, shows strong antitumor activity in pancreatic ductal adenocarcinoma models with high selectivity and tolerable dosing.

This study compares proteogenomic profiles of right-sided colon cancer, left-sided colon cancer, and rectal cancers, revealing distinct mutational and protein interaction patterns.